Ekso Non Current Assets Total vs Net Receivables Analysis
EKSO Stock | USD 1.37 0.08 5.52% |
Ekso Bionics financial indicator trend analysis is much more than just examining Ekso Bionics Holdings latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ekso Bionics Holdings is a good investment. Please check the relationship between Ekso Bionics Non Current Assets Total and its Net Receivables accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Non Current Assets Total vs Net Receivables
Non Current Assets Total vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ekso Bionics Holdings Non Current Assets Total account and Net Receivables. At this time, the significance of the direction appears to have very week relationship.
The correlation between Ekso Bionics' Non Current Assets Total and Net Receivables is 0.23. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Ekso Bionics Holdings, assuming nothing else is changed. The correlation between historical values of Ekso Bionics' Non Current Assets Total and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Ekso Bionics Holdings are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Non Current Assets Total i.e., Ekso Bionics' Non Current Assets Total and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.23 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Net Receivables
Most indicators from Ekso Bionics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ekso Bionics Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. As of the 17th of May 2024, Sales General And Administrative To Revenue is likely to grow to 1.01, while Selling General Administrative is likely to drop about 8.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 6.7M | 6.2M | 9.7M | 5.1M | Total Revenue | 11.2M | 12.9M | 18.3M | 12.3M |
Ekso Bionics fundamental ratios Correlations
Click cells to compare fundamentals
Ekso Bionics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ekso Bionics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 21.9M | 20.6M | 49.2M | 40.9M | 28.9M | 26.0M | |
Short Long Term Debt Total | 3.9M | 3.9M | 2.2M | 7.5M | 7.2M | 3.7M | |
Other Current Liab | 1.7M | 1.4M | 2.3M | 2.3M | 2.7M | 2.3M | |
Total Current Liabilities | 7.8M | 5.0M | 6.9M | 9.2M | 8.1M | 6.6M | |
Total Stockholder Equity | 6.8M | 4.4M | 37.2M | 25.4M | 12.6M | 13.6M | |
Net Debt | (7M) | (9.0M) | (38.2M) | (13.0M) | (1.5M) | (1.5M) | |
Retained Earnings | (183.3M) | (199.1M) | (208.9M) | (223.9M) | (239.1M) | (227.2M) | |
Cash | 10.9M | 12.9M | 40.4M | 20.5M | 8.6M | 16.1M | |
Cash And Short Term Investments | 10.9M | 12.9M | 40.4M | 20.5M | 8.6M | 8.2M | |
Common Stock Total Equity | 60K | 63K | 87K | 8K | 9.2K | 8.7K | |
Liabilities And Stockholders Equity | 21.9M | 20.6M | 49.2M | 40.9M | 28.9M | 26.0M | |
Non Current Liabilities Total | 7.3M | 11.2M | 5.1M | 6.3M | 8.2M | 7.4M | |
Total Liab | 15.1M | 16.2M | 11.9M | 15.5M | 16.3M | 13.4M | |
Total Current Assets | 18.8M | 18.4M | 47.8M | 31.0M | 20.2M | 22.1M | |
Short Term Debt | 2.8M | 548K | 229K | 2.7M | 1.6M | 1.1M | |
Common Stock | 63K | 87K | 8K | 13K | 15K | 14.3K | |
Common Stock Shares Outstanding | 4.8M | 7.2M | 12.3M | 13.0M | 13.9M | 14.6M | |
Other Stockholder Equity | 189.9M | 204.4M | 246.1M | 248.8M | 251.6M | 179.6M | |
Other Liab | 6.2M | 7.9M | 3.1M | 1.4M | 1.3M | 1.2M | |
Net Tangible Assets | 6.6M | 4.4M | 37.2M | 19.8M | 22.8M | 15.5M | |
Property Plant And Equipment Net | 2.7M | 1.9M | 1.2M | 4.0M | 3.0M | 2.7M | |
Current Deferred Revenue | 1.5M | 1.5M | 1.2M | 1.1M | 2.0M | 1.4M | |
Accounts Payable | 1.9M | 1.5M | 3.1M | 3.2M | 1.8M | 2.5M | |
Non Current Assets Total | 3.1M | 2.2M | 1.4M | 9.9M | 8.7M | 5.0M | |
Non Currrent Assets Other | 178K | 320K | 164K | 231K | 392K | 504.2K | |
Other Assets | 134K | 178K | 1.0M | 164K | 147.6K | 140.2K | |
Long Term Debt | 407K | 9.1M | 2.0M | 3.8M | 4.8M | 3.8M | |
Net Receivables | 5.2M | 3.4M | 4.7M | 4.6M | 5.6M | 3.9M | |
Long Term Debt Total | 4.8M | 2.6M | 407K | 9.1M | 10.5M | 11.0M | |
Capital Surpluse | 165.8M | 173.9M | 189.9M | 204.4M | 235.0M | 165.0M | |
Inventory | 2.5M | 2.0M | 2.2M | 5.2M | 5.1M | 2.9M | |
Other Current Assets | 238K | 191K | 485K | 700K | 875K | 597.9K | |
Property Plant And Equipment Gross | 2.7M | 1.9M | 1.2M | 4.0M | 6.2M | 6.5M | |
Accumulated Other Comprehensive Income | 50K | (847K) | (17K) | 563K | 156K | 163.8K | |
Property Plant Equipment | 2.7M | 1.2M | 1.2M | 4.0M | 4.6M | 2.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Ekso Stock analysis
When running Ekso Bionics' price analysis, check to measure Ekso Bionics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ekso Bionics is operating at the current time. Most of Ekso Bionics' value examination focuses on studying past and present price action to predict the probability of Ekso Bionics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ekso Bionics' price. Additionally, you may evaluate how the addition of Ekso Bionics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Ekso Bionics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.202 | Quarterly Revenue Growth (0.09) | Return On Assets (0.26) | Return On Equity (0.81) |
The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.